Literature DB >> 15174181

Fragmentation of biotinylated cyclic peptides.

Michael E Lassman1, Nadia Kulagina, Chris Rowe Taitt.   

Abstract

Electrospray ionization coupled with tandem mass spectrometry (MS/MS) was used to determine the preferred binding site(s) of biotin NHS ester with a series of cyclic peptides with antibiotic properties. The peptides investigated are polymyxins, cyclic peptides produced by Bacillus polymyxa. In spite of the 1:1 stoichiometry used in the labeling reaction, multiple biotin molecules were incorporated into intact polymyxin peptides. Given the amine specificity of the activated biotin and the large number of amino acids with primary amines in the polymyxins, it was not clear by inspection which binding sites were more reactive than others. MS/MS was used to characterize the structure of the biotinylated peptides. MS/MS spectra of cyclic peptides often lead to ambiguous structure determinations due to the potential for multiple ring openings which result in the generation of multiple ion series. The MS/MS spectra of polymyxin peptides are especially difficult to characterize due to the lack of variety in their amino acids; however, the added complexity of the biotin aided the elucidation of the fragmentation pathways. MS/MS spectra of the species with biotin additions were used to rationalize the preferential binding sites of these molecules.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15174181     DOI: 10.1002/rcm.1483

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  1 in total

1.  Chemometrics and genome mining reveal an unprecedented family of sugar acid-containing fungal nonribosomal cyclodepsipeptides.

Authors:  Chen Wang; Dongliang Xiao; Baoqing Dun; Miaomiao Yin; Adigo Setargie Tsega; Linan Xie; Wenhua Li; Qun Yue; Sibao Wang; Han Gao; Min Lin; Liwen Zhang; István Molnár; Yuquan Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2022-08-01       Impact factor: 12.779

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.